A committee of the European Medicines Agency (EMEA) will hold a meeting this week related to its investigation into the cases of suicidal thoughts after taking diabetes and weight loss medications such as Novo Nordisk’s Ozempicshowed the organization’s agenda on Monday.
The agency began reviewing this class of diabetes and weight loss drugs, known as GLP-1 receptor agonists, last July after the Icelandic health regulator flagged three cases of patients thinking about suicide. or get injured after taking Novo’s drugs: the diabetes medicine Ozempic and the weight loss treatment Saxenda.
The list of drugs investigated by the EU regulator includes Rybelsus, Saxenda, Victoza and Xultophy, as well as Ozempic and Wegovy.
In January of this year, the United States Food and Drug Administration (FDA) conducted a preliminary study in which it found no such relationship. Still, he cautioned that he could not definitively rule out a small risk due to the paucity of data.
GLP-1 receptor agonists originally developed to help control blood sugar in patients with diabetes, they also slow digestion and reduce hunger.
The Suicide Care Center (CAS) serves anonymously, free and voluntarily on line 135. The technique it uses is “active listening”, with interventions aimed at getting the consultant to speak.
The line is free calling from CABA or Greater Buenos Aires; and the numbers (011) 5275-1135 or 0800 345 1435 are for the entire country.
Source: Ambito
I am an author and journalist who has worked in the entertainment industry for over a decade. I currently work as a news editor at a major news website, and my focus is on covering the latest trends in entertainment. I also write occasional pieces for other outlets, and have authored two books about the entertainment industry.
